Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 49 results:
Συντάκτης Τίτλος Τύπος [ Έτος(Asc)]
Φίλτρα: Συντάκτης is Christodoulou, Christos  [Clear All Filters]
2016
Mountzios, G., Aravantinos G., Alexopoulou Z., Timotheadou E., Matsiakou F., Christodoulou C., et al. (2016).  Lessons from the past: Long-term safety and survival outcomes of a prematurely terminated randomized controlled trial on prophylactic vs. hemoglobin-based administration of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia.. Mol Clin Oncol. 4(2), 211-220.
Gogas, H., Kotoula V., Alexopoulou Z., Christodoulou C., Kostopoulos I., Bobos M., et al. (2016).  MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer.. J Transl Med. 14(1), 136.
Fountzilas, G., Giannoulatou E., Alexopoulou Z., Zagouri F., Timotheadou E., Papadopoulou K., et al. (2016).  TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.. Oncotarget. 7(22), 32731-53.
2015
Koutras, A., Kalogeras K. T., Wirtz R. M., Alexopoulou Z., Bobos M., Zagouri F., et al. (2015).  Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study.. J Transl Med. 13, 171.
Pavlakis, K., Bobos M., Batistatou A., Kotoula V., Eleftheraki A. G., Stofas A., et al. (2015).  p85 protein expression is associated with poor survival in HER2-positive patients with advanced breast cancer treated with trastuzumab.. Pathol Oncol Res. 21(2), 273-82.
Papaxoinis, G., Kotoula V., Alexopoulou Z., Kalogeras K. T., Zagouri F., Timotheadou E., et al. (2015).  Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study.. PLoS One. 10(10), e0140293.
Koutsoukos, K., Tzannis K., Christodoulou C., Karavasilis V., Bakoyiannis C., Makatsoris T., et al. (2015).  Two cycles of adjuvant carboplatin in stage I seminoma: 8-year experience by the Hellenic Cooperative Oncology Group (HECOG).. World J Urol.
2014
Kotoula, V., Bobos M., Alexopoulou Z., Papadimitriou C., Papadopoulou K., Charalambous E., et al. (2014).  Adjusting breast cancer patient prognosis with non-HER2-gene patterns on chromosome 17.. PLoS One. 9(8), e103707.
Fountzilas, G., Dafni U., Papadimitriou C., Timotheadou E., Gogas H., Eleftheraki A. G., et al. (2014).  Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial.. BMC Cancer. 14, 515.
Pentheroudakis, G., Kotoula V., Fountzilas E., Kouvatseas G., Basdanis G., Xanthakis I., et al. (2014).  A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: a translational research study of the Hellenic Cooperative Oncology Group (HeCOG).. BMC Cancer. 14, 111.
2013
Stavropoulou, A. V., Fostira F., Pertesi M., Tsitlaidou M., Voutsinas G. E., Triantafyllidou O., et al. (2013).  Prevalence of BRCA1 mutations in familial and sporadic greek ovarian cancer cases.. PLoS One. 8(3), e58182.
Pentheroudakis, G., Kotoula V., Eleftheraki A. G., Tsolaki E., Wirtz R. M., Kalogeras K. T., et al. (2013).  Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG).. PLoS One. 8(7), e70634.
2012
Korantzis, I., Kalogeras K. T., Papaxoinis G., Kotoula V., Koutras A., Soupos N., et al. (2012).  Expression of angiogenic markers in the peripheral blood of patients with advanced breast cancer treated with weekly docetaxel.. Anticancer Res. 32(10), 4569-80.
Kotoula, V., Krikelis D., Karavasilis V., Koletsa T., Eleftheraki A. G., Televantou D., et al. (2012).  Expression of DNA repair and replication genes in non-small cell lung cancer (NSCLC): a role for thymidylate synthetase (TYMS).. BMC Cancer. 12, 342.
Fountzilas, G., Valavanis C., Kotoula V., Eleftheraki A. G., Kalogeras K. T., Tzaida O., et al. (2012).  HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.. J Transl Med. 10, 10.
Razis, E., Kalogeras K. T., Kotoula V., Eleftheraki A. G., Nikitas N., Kronenwett R., et al. (2012).  Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression.. Clin Breast Cancer. 12(3), 183-93.
Murray, S., Karavasilis V., Bobos M., Razis E., Papadopoulos S., Christodoulou C., et al. (2012).  Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer.. J Exp Clin Cancer Res. 31, 77.
Gogas, H., Dafni U., Karina M., Papadimitriou C., Batistatou A., Bobos M., et al. (2012).  Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial.. Breast Cancer Res Treat. 132(2), 609-19.
Fountzilas, G., Christodoulou C., Bobos M., Kotoula V., Eleftheraki A. G., Xanthakis I., et al. (2012).  Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab.. J Transl Med. 10, 212.
2011
Fountzilas, G., Kourea H. P., Bobos M., Televantou D., Kotoula V., Papadimitriou C., et al. (2011).  Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation.. Anticancer Res. 31(9), 3007-18.
2010
Kalofonos, H. P., Papakostas P., Makatsoris T., Papamichael D., Vourli G., Xanthakis I., et al. (2010).  Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer.. Anticancer Res. 30(10), 4325-33.
Bamias, A., Karadimou A., Lampaki S., Lainakis G., Malettou L., Timotheadou E., et al. (2010).  Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model.. BMC Cancer. 10, 45.
Bafaloukos, D., Linardou H., Aravantinos G., Papadimitriou C., Bamias A., Fountzilas G., et al. (2010).  A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study.. BMC Med. 8, 3.
2009
Christodoulou, C., Kostopoulos I., Kalofonos H. P., Lianos E., Bobos M., Briasoulis E., et al. (2009).  Trastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer. phase II Study of the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation.. Oncology. 76(4), 275-85.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές